New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
04:55 EDTSTAA, STAA, STAA, VTL, VTL, VTL, ANAC, ANAC, ANAC, PTCT, PTCT, PTCT, SGMO, SGMO, SGMO, RNA, RNA, RNA, BLUE, BLUE, BLUE, BIND, BIND, BIND, FCSC, FCSC, FCSC, CRDC, CRDC, CRDC, DRTX, DRTX, DRTXWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
News For DRTX;CRDC;FCSC;BIND;BLUE;RNA;SGMO;PTCT;ANAC;VTL;STAA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
10:02 EDTPTCTOn the Fly: Analyst Initiation Summary
Subscribe for More Information
January 22, 2015
16:15 EDTPTCTPTC Therapeutics initiated with an Outperform at RBC Capital
Subscribe for More Information
07:43 EDTBLUEbluebird bio reinstated with a Buy at BofA/Merrill
Subscribe for More Information
January 21, 2015
12:27 EDTBLUEbluebird bio price target raised to $146 from $94 at Wedbush
Subscribe for More Information
January 20, 2015
13:21 EDTBLUECAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link
January 13, 2015
08:53 EDTRNAProsensa announces holder approval of certain matters relating to BioMarin
Subscribe for More Information
January 12, 2015
08:19 EDTVTLVital Therapies provides clinical, regulatory update
Vital Therapies provided an update on its clinical trial programs and regulatory matters. 193 of a targeted 200 subjects have been enrolled in VTI-208, the company's randomized, controlled, open-label Phase 3 clinical trial in alcohol induced liver decompensation. Forty-six clinical sites are now open in the U.S., UK, Spain and Australia. The company expects to complete enrollment around the end of January and remains on track to announce topline data in 2Q15. The primary endpoint of VTI-208 is overall survival through at least study day 91. If VTI-208 is statistically and clinically successful, the company plans to submit a Biologics License Application, or BLA, to the FDA in the first half of 2016. The company continues to expect topline data from both the VTI-210 and VTI-212 clinical trials in 2016. VTI-210, the company's second Phase 3 trial, is a randomized, controlled, open-label study evaluating the ELAD System in severe acute alcoholic hepatitis, or AAH, patients who have failed standard therapy. VTI-212 is a single-arm Phase 2 trial, evaluating the ELAD System in patients with either fulminant hepatic failure or surgery-induced liver failure. On the regulatory front, the company recently received approval of its German Clinical Trial Application and can now begin to open sites and enroll subjects in its VTI-210 trial. The company expects to open up to 10 sites in Germany for VTI-210 in the next year, which will augment the existing VTI-210 sites in the USA, UK and Spain. Additionally, the company recently received regulatory guidance responses from the FDA concerning its submission regarding chemistry, manufacturing, and controls topics. The company believes that this guidance, which covered both the biologic and delivery components of ELAD, is consistent with the company's current plans as well as prior interactions with the agency.
07:21 EDTSGMO, BLUEEBD Group to hold a conference
Subscribe for More Information
07:05 EDTSGMOSangamo provides update on ZFP Therapeutic programs
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use